A Phase I Dose Escalation Study of Intravenous Decitabine in Combination With Oral Bexarotene in Patients With Acute Myeloid Leukemia (AML)
The investigators are seeking to study the combination of decitabine and bexarotene. These
two agents have each shown efficacy in decreasing leukemic blast counts and restoring normal
hematopoiesis via different mechanisms of action and with non-overlapping side-effect
profiles. By combining these agents, the investigators hope to improve overall response
rates. The investigators further hope to improve platelet and neutrophil counts in an even
greater number of patients, thus treating two of the most important sources of morbidity and
mortality in this patient population.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity of combination decitabine and bexarotene during four cycles of therapy
After 4 cycles of therapy
Amanda Cashen, M.D.
Washington University School of Medicine
United States: Institutional Review Board
09-1661 / 201012801
|Washington University School of Medicine||Saint Louis, Missouri 63110|